Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Edivoxetine hydrochloride by Eli Lilly and Co for Attention Deficit Hyperactivity Disorder (ADHD): Likelihood of Approval
Edivoxetine hydrochloride is under clinical development by Eli Lilly and Co and currently in Phase III for Attention Deficit Hyperactivity...